doi:10.48130/targetome-0026-0043

[1]

Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. 2004. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329:15−19

doi: 10.1136/bmj.329.7456.15

[2]

Hayward S, Hole B, Denholm R, Duncan P, Morris JE, et al. 2021. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study. Nephrology Dialysis Transplantation 36:503−511

doi: 10.1093/ndt/gfaa064

[3]

Steinman MA, Hanlon JT. 2010. Managing medications in clinically complex elders: there's got to be a happy medium. JAMA 304:1592−1601

doi: 10.1001/jama.2010.1482

[4]

Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, et al. 2003. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289:1107−1116

doi: 10.1001/jama.289.9.1107

[5]

Turgeon J, Michaud V, Steffen L. 2017. The dangers of polypharmacy in elderly patients. JAMA Internal Medicine 177:1544

doi: 10.1001/jamainternmed.2017.4790

[6]

Leopold JA, Loscalzo J. 2018. Emerging role of precision medicine in cardiovascular disease. Circulation Research 122:1302−1315

doi: 10.1161/circresaha.117.310782

[7]

Haga SB, Burke W. 2004. Using pharmacogenetics to improve drug safety and efficacy. JAMA 291:2869−2871

doi: 10.1001/jama.291.23.2869

[8]

Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, et al. 2023. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet 401:347−356

doi: 10.1016/S0140-6736(22)01841-4

[9]

van der Wouden CH, Bank PCD, Özokcu K, Swen JJ, Guchelaar HJ. 2019. Pharmacist-initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes 10:416

doi: 10.3390/genes10060416

[10]

Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, et al. 2023. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics 114:51−68

doi: 10.1002/cpt.2903

[11]

Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, et al. 2013. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical Pharmacology & Therapeutics 93:402−408

doi: 10.1038/clpt.2013.2

[12]

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics 90:328−332

doi: 10.1038/clpt.2011.132

[13]

Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, et al. 2021. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing. Clinical Pharmacology & Therapeutics 109:1417−1423

doi: 10.1002/cpt.2015

[14]

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, et al. 2017. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clinical Pharmacology & Therapeutics 102:45−51

doi: 10.1002/cpt.583

[15]

Huang Q, Liao Y, Yu T, Lei W, Liang H, et al. 2023. A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China. Journal of Clinical Laboratory Analysis 37:e24855

doi: 10.1002/jcla.24855

[16]

Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, et al. 2021. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine 23:2335−2341

doi: 10.1038/s41436-021-01269-9

[17]

Weintraub WS, Fahed AC, Rumsfeld JS. 2018. Translational medicine in the era of big data and machine learning. Circulation Research 123:1202−1204

doi: 10.1161/circresaha.118.313944

[18]

Caraballo PJ, Sutton JA, Giri J, Wright JA, Nicholson WT, et al. 2020. Integrating pharmacogenomics into the electronic health record by implementing genomic indicators. Journal of the American Medical Informatics Association 27:154−158

doi: 10.1093/jamia/ocz177

[19]

Chenchula S, Atal S, Uppugunduri CRS. 2024. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. The Pharmacogenomics Journal 24:9

doi: 10.1038/s41397-024-00326-1

[20]

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, et al. 2021. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics 110:563−572

doi: 10.1002/cpt.2350

[21]

Sadee W, Wang D, Hartmann K, Toland AE. 2023. Pharmacogenomics: driving personalized medicine. Pharmacological Reviews 75:789−814

doi: 10.1124/pharmrev.122.000810

[22]

Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. 2020. Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Frontiers in Pharmacology 11:595219

doi: 10.3389/fphar.2020.595219

[23]

Chanfreau-coffinier C, Hull LE, Lynch JA, DuVall SL, Damrauer SM, et al. 2019. Projected prevalence of actionable pharmacogenetic variants and level A drugs prescribed among US Veterans Health Administration pharmacy users. JAMA Network Open 2:e195345

doi: 10.1001/jamanetworkopen.2019.5345

[24]

Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, et al. 2015. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual Review of Pharmacology and Toxicology 55:89−106

doi: 10.1146/annurev-pharmtox-010814-124835

[25]

Liu D, Olson KL, Manzi SF, Mandl KD. 2021. Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics. Genetics in Medicine 23:782−786

doi: 10.1038/s41436-020-01044-2

[26]

Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, et al. 2020. Prescribing prevalence of medications with potential genotype-guided dosing in pediatric patients. JAMA Network Open 3:e2029411

doi: 10.1001/jamanetworkopen.2020.29411

[27]

Smith DM, Peshkin BN, Springfield TB, Brown RP, Hwang E, et al. 2020. Pharmacogenetics in practice: estimating the clinical actionability of pharmacogenetic testing in perioperative and ambulatory settings. Clinical and Translational Science 13:618−627

doi: 10.1111/cts.12748

[28]

Yu S, Zhang Y, Yao Y, Cao H. 2020. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. The Journal of Headache and Pain 21:53

doi: 10.1186/s10194-020-01117-2

[29]

国家统计局 [National Bureau of Statistics of China]. 2023. 东西中部和东北地区划分方法 [Division of China's eastern, central, western and northeastern regions]. www.stats.gov.cn/zt_18555/zthd/sjtjr/dejtjkfr/tjkp/202302/t20230216_1909741.htm (in Chinese)

[30]

Kimpton JE, Carey IM, Threapleton CJD, Robinson A, Harris T, et al. 2019. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: an analysis to inform design of pre-emptive pharmacogenomic testing. British Journal of Clinical Pharmacology 85:2734−2746

doi: 10.1111/bcp.14100

[31]

Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, et al. 2012. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clinical Pharmacology & Therapeutics 92:235−242

doi: 10.1038/clpt.2012.66

[32]

广东省医疗保障局 [Healthcare Security Administration of Guangdong Province]. 2024. 广东省医疗保障局关于公布"药物基因多态性检测"等转归医疗服务价格项目的通知 [Notice of Guangdong Healthcare Security Administration on publishing the converted medical service price items such as 'pharmacogene polymorphism testing']. https://hsa.gd.gov.cn/zwgk/content/post_4608065.html (in Chinese)

[33]

河北省医疗保障局 [Hebei Provincial Healthcare Security Administration]. 2024. 河北省城市公立医院医疗服务价格查询表 [Hebei Province urban public hospitals medical service price inquiry table]. https://ylbzj.hebei.gov.cn/cms/content/3351 (in Chinese)

[34]

浙江省物价局, 浙江省卫生计生委, 浙江省人力资源和社会保障厅 [Price Bureau of Zhejiang Province, Health and Family Planning Commission of Zhejiang Province, Department of Human Resources and Social Security of Zhejiang Province]. 2019. 浙江省卫生计生委浙江省人力资源和社会保障厅关于完善和新增部分医疗服务检验项目及价格等有关事项的通知 [Notice of the Zhejiang provincial authorities on improving and adding medical service testing items and prices]. http://ybj.zj.gov.cn/art/2019/11/6/art_1229113757_564072.html (in Chinese)

[35]

Samwald M, Xu H, Blagec K, Empey PE, Malone DC, et al. 2016. Incidence of exposure of patients in the United States to multiple drugs for which pharmacogenomic guidelines are available. PLoS One 11:e0164972

doi: 10.1371/journal.pone.0164972

[36]

Mostafa S, Kirkpatrick CMJ, Byron K, Sheffield L. 2019. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5,408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. Journal of Neural Transmission 126:5−18

doi: 10.1007/s00702-018-1922-0

[37]

Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, et al. 2016. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. The Journal of Molecular Diagnostics 18:438−445

doi: 10.1016/j.jmoldx.2016.01.003

[38]

Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, et al. 2022. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics 112:959−967

doi: 10.1002/cpt.2526

[39]

Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, et al. 2022. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clinical Pharmacology & Therapeutics 111:1007−1021

doi: 10.1002/cpt.2557

[40]

Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, et al. 2017. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics 102:397−404

doi: 10.1002/cpt.668

[41]

Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, et al. 2020. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clinical Pharmacology & Therapeutics 108:191−200

doi: 10.1002/cpt.1830

[42]

Wang X, Yang S, Zhang J, Wang M, Zhang J, et al. 2022. Transformer-based unsupervised contrastive learning for histopathological image classification. Medical Image Analysis 81:102559

doi: 10.1016/j.media.2022.102559

[43]

Wang X, Du Y, Yang S, Zhang J, Wang M, et al. 2023. RetCCL: clustering-guided contrastive learning for whole-slide image retrieval. Medical Image Analysis 83:102645

doi: 10.1016/j.media.2022.102645

[44]

Wang X, Zhao J, Marostica E, Yuan W, Jin J, et al. 2024. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature 634:970−978

doi: 10.1038/s41586-024-07894-z

[45]

Yuan W, Chen Y, Zhu B, Yang S, Zhang J, et al. 2025. Pancancer outcome prediction via a unified weakly supervised deep learning model. Signal Transduction and Targeted Therapy 10:285

doi: 10.1038/s41392-025-02374-w

[46]

Cai D, Chen J, Zhao J, Xue Y, Yang S, et al. 2024. HiCervix: an extensive hierarchical dataset and benchmark for cervical cytology classification. IEEE Transactions on Medical Imaging 43:4344−4355

doi: 10.1109/TMI.2024.3419697

[47]

Wang X, Zhang J, Yang S, Xiang J, Luo F, et al. 2023. A generalizable and robust deep learning algorithm for mitosis detection in multicenter breast histopathological images. Medical Image Analysis 84:102703

doi: 10.1016/j.media.2022.102703

[48]

Guo R, Xie K, Pagnucco M, Song Y. 2023. SAC-Net: learning with weak and noisy labels in histopathology image segmentation. Medical Image Analysis 86:102790

doi: 10.1016/j.media.2023.102790

[49]

Ding PA, Yang S, Meng LJ, Chen S, Li SP, et al. 2026. A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer. Annals of Oncology 2026:In press

doi: 10.1016/j.annonc.2026.07.004

[50]

Ianni BD, Yiu CH, Tan ECK, Lu CY. 2025. Real-world utilization of medications with pharmacogenetic recommendations in older adults: a scoping review. Clinical and Translational Science 18:e70126

doi: 10.1111/cts.70126

[51]

Lemke LK, Alam B, Williams R, Starostik P, Cavallari LH, et al. 2023. Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States. Frontiers in Pharmacology 14:1179364

doi: 10.3389/fphar.2023.1179364